Plan for tiny Medicare payment hike would hurt seniors, some warn

CMS proposed a meager 0.09% average increase to Medicare Advantage (MA) payment rates for 2027—well below analysts' expectations of roughly 4–6% and last year’s 5.06%—prompting insurers to warn that benefits may be cut or costs raised for about 35 million beneficiaries. The reduction reflects an update to risk-adjustment data (moving to 2023–24 data from 2018–19, ~3.5% down) and a policy to exclude chart-review-only diagnoses (~1.5% down); CMS is taking comments through March 1 with a final rate due April 6. The move follows scrutiny of chart-review coding (KFF cites an estimated $24 billion in extra MA payments in 2023 and Kaiser affiliates paid $556 million to settle related allegations), and could compress MA plan margins and lead insurers to raise premiums or trim benefits.

Analysis

Market structure: A near-flat 0.09% MA payment update shifts ~35M enrollee economics toward insurers absorbing margin pressure or cutting benefits; MA-focused players (Humana, certain regional players) face the largest revenue-impact concentration while diversified players (UNH, CVS, ELV) can offset via commercial/PBM lines. Expect pricing power compression on MA product lines, potential benefit narrowing, and selective network/prior‑auth tightening rather than immediate mass exits. The April 6 final rule and Oct 2026 renewal window create discrete decision points for carriers and product repricing.

Risk assessment: Tail risks include (1) a final rule deeper than proposed (net negative >2% revenue for MA books) triggering rating downgrades and widening insurer credit spreads, and (2) successful litigation/legislative pushback restoring prior coding that would reverse losses. Immediate risk window: public comment close (Mar 1) and final rule (Apr 6); earnings/margin pressure materializes into commercial actions by Q3–Q4 2026 ahead of plan renewals. Hidden dependency: insurers’ ability to extract PBM and commercial margin (Caremark, Optum) buffers MA shortfalls.

Trade implications: Short selective MA-concentrated equities (HUM, smaller regional MA specialists) and buy diversified insurers (UNH, CVS, ELV) or healthcare services providers likely to gain share if MA narrows benefits (home health, SNF beneficiaries volatility). Use options into Apr 6 and Oct renewal windows — buy puts or put spreads on HUM/CI with expiries 1–6 months post-April and sell calls on UNH/CVS to finance. Monitor 5y insurer CDS and IG spreads; buy protection if spreads widen >25bps vs. current.

Contrarian angle: Market may overprice perpetual margin loss; historically insurers leaned on utilization management and product redesign before passing full costs — earnings impact could be modest (mid-single-digit EPS % for big diversified insurers). If final rule stays at ~0%, short-duration options and small tactical shorts on HUM (1–2% portfolio) while establishing 2–3% longs in UNH/CVS could capture mean-reversion if insurers retain pricing power or litigation eases.

Key Decisions for Investors

• Establish a 1.5% portfolio short position in HUM (Humana) ahead of Apr 6 final rule, sizing to be increased to 3% if final rule reduces MA effective payments by >0.5%; hedge with May 2026 put spreads (5–10% OTM) to cap cost.
• Take a 2–3% long position in UNH (UnitedHealth) and a 1% long in CVS to play diversification/PBM insulation; finance ~50% of CVS purchase by selling May–Jul 2026 covered calls 8–12% OTM.
• Implement a relative-value pair: long UNH (2%) / short HUM (1.5%) to capture differential exposure to MA risk and PBM diversification, rebalance on Apr 7 after final rule and again on Oct 1 before 2027 renewals.
• Buy corporate credit protection (e.g., 5y CDS or equivalent bond puts) on a basket of mid‑cap MA-focused insurers if their 5y CDS widens >25bps from current levels or if ratings agencies issue negative outlooks post-April.
• Trigger rules: if final rule publishes an increase ≥0.5% (less negative), close >50% of short exposure within 5 trading days; if final ≤0% or litigation fails to reverse changes by Sep 1, increase short sizing by another 1–1.5% and shift into longer-dated puts (Oct–Jan 2027 expiries).